SCHEMBL25880892

SCHEMBL25880892

OCCCOc1cc(Cl)nnc1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.36
ALDH1A1 P00352 2/20 0.34
LMNA P02545 2/20 0.34
LOX P28300 1/20 0.34
AOC3 Q16853 1/20 0.34
S1PR4 O95977 1/20 0.33
TP53 P04637 2/20 0.33
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RECQL P46063 1/20 0.32
F10 P00742 1/20 0.32
PDE5A O76074 1/20 0.32
TUBB1 Q9H4B7 1/20 0.32
IRAK4 Q9NWZ3 2/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31
PRKAB2 O43741 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2767989 0.91 TDP1 (0.38) TDP1ALDH1A1LMNALOXAOC3
SCHEMBL30310964 0.91 TDP1 (0.38) TDP1ALDH1A1LMNALOXAOC3
SCHEMBL25880866 0.81 TDP1 (0.36) TDP1LMNAS1PR4
SCHEMBL25880792 0.79 ENPP1 (0.43) TDP1ALDH1A1S1PR4TP53L3MBTL1
SCHEMBL22445196 0.79 TDP1 (0.38) TDP1
SCHEMBL30936658 0.79 TDP1 (0.38) TDP1
SCHEMBL20839734 0.78 PLAU (0.41) TDP1ALDH1A1LMNAS1PR4MAPK1
SCHEMBL30042712 0.76 TDP1 (0.35) TDP1ALDH1A1LMNA
SCHEMBL25880994 0.75 KDM4E (0.36) TDP1S1PR4
SCHEMBL25880894 0.75 TDP1 (0.32) TDP1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING RBM17, SF3B1, SF3B5 TDP1 387/4885ALDH1A1 3962/4885LMNA 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.